<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325441</url>
  </required_header>
  <id_info>
    <org_study_id>BBI608-201</org_study_id>
    <nct_id>NCT01325441</nct_id>
  </id_info>
  <brief_title>A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Oncology, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608&#xD;
      in combination with paclitaxel in patients with advanced malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multi-center, single arm phase 1 dose escalation study and phase 2&#xD;
      study of BBI608 in combination with paclitaxel in patients with advanced solid tumors for&#xD;
      whom weekly paclitaxel is an acceptable option.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety by reporting the adverse events and serious adverse events</measure>
    <time_frame>The time from the date of first treatment, while the patient is taking napabucasin, and for 30 days after stopping therapy, an average of 6 months</time_frame>
    <description>Assessment of safety of napabucasin given in combination with paclitaxel in patients with advanced malignancies by reporting of adverse events and serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the Recommended Phase 2 Dose by assessing dose-limiting toxicities (DLTs)</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of the Recommended Phase 2 dose (RP2D) of napabucasin when administered with paclitaxel in patients with advanced malignancies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity of BBI608 when administered in combination with paclitaxel in patients with advanced malignancies by performing tumor assessments every 8 weeks</measure>
    <time_frame>Anti-tumor activity is assessed every 8 weeks, from the first dose of BBI608 to 30 days after the last dose of BBI608, an expected average of 6 months</time_frame>
    <description>To assess the preliminary anti-tumor activity of napabucasin administered in combination with paclitaxel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of BBI608 and paclitaxel assessed by area under the plasma concentration versus time curve</measure>
    <time_frame>On Day 3 and Day 17 of the first cycle prior to dosing and 0.5, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 8.5, 9, 10, 11, 24 and 27 hours after first dose</time_frame>
    <description>Blood sampling to assess the pharmacokinetic profile of BBI608 administered in combination with paclitaxel.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">565</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>BBI608 and Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive BBI608 orally continuously at dose levels specified for their respective dose cohorts. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI608</intervention_name>
    <arm_group_label>BBI608 and Paclitaxel</arm_group_label>
    <other_name>Napabucasin</other_name>
    <other_name>BB608</other_name>
    <other_name>BBI-608</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>BBI608 and Paclitaxel</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent must be obtained and documented according to&#xD;
             International Conference on Harmonization (ICH)- Good Clinical Practice (GCP), the&#xD;
             local regulatory requirements, and permission to use private health information in&#xD;
             accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior&#xD;
             to study-specific screening procedures&#xD;
&#xD;
          2. A histologically or cytologically confirmed ovarian, breast, non-small cell lung,&#xD;
             melanoma, gastric/GEJ/esophageal or other type of advanced cancer that is metastatic,&#xD;
             unresectable, or recurrent and for which weekly paclitaxel is an acceptable&#xD;
             therapeutic option.&#xD;
&#xD;
          3. Patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer must&#xD;
             also meet the following criteria: a. Must be either platinum-resistant or&#xD;
             platinum-refractory according to the following definitions:(1)Platinum-resistant: a&#xD;
             response to platinum therapy followed by progression within 6 months after completing&#xD;
             therapy (2)Platinum-refractory: best response of stable disease or progression during&#xD;
             platinum therapy; b. Must have had prior systemic treatment with a taxane; c. Must&#xD;
             have received no more than 4 prior systemic cytotoxic regimens&#xD;
&#xD;
          4. Patients with melanoma must also meet the following criteria: a. If melanoma is BRAF&#xD;
             wild-type or has BRAF mutations that are not amenable to BRAF inhibitor therapy, and&#xD;
             the patient is a candidate for immunotherapy, must have received ipilimumab; b. If&#xD;
             melanoma is positive for the V600E or V600K BRAF mutation, must have received at least&#xD;
             one line of prior therapy with a BRAF-specific inhibitor; either alone or in&#xD;
             combination.&#xD;
&#xD;
          5. Patients with triple negative breast cancer (estrogen receptor-negative (ER-),&#xD;
             progesterone receptor-negative (PR-), and human epidermal growth factor receptor&#xD;
             2-negative (Her2-) must also meet the following criteria: a. Must have received at&#xD;
             least one prior chemotherapy regimen for locally advanced or metastatic disease; b.&#xD;
             Must have received prior taxane therapy.&#xD;
&#xD;
          6. Patients with NSCLC (adenocarcinoma, squamous, or adenosquamous histopathology) must&#xD;
             also meet the following criteria: a. Must have disease that is stage IIIB, not curable&#xD;
             by surgery or radiotherapy, or stage IV; b. Must have received at least one prior&#xD;
             chemotherapy regimen for locally advanced or metastatic disease; c. EGFR-positive or&#xD;
             ALK-positive patients must have received at least one line of EGFR-directed or&#xD;
             ALK-directed therapy, respectively; d. Must have received prior taxane therapy.&#xD;
&#xD;
          7. Patients with adenocarcinoma arising from the esophagus, gastroesophageal junction, or&#xD;
             stomach must also meet the following criteria: a. Must have received prior treatment&#xD;
             with a platinum/fluoropyrimidine-based therapy with or without an anthracycline in the&#xD;
             metastatic setting; or, in the adjuvant setting if recurrence occurred within 6 months&#xD;
             of completing systemic adjuvant treatment; b. Patients with HER2 positive tumors must&#xD;
             have had prior treatment with a Her2 inhibitor (e.g. trastuzumab or lapatinib); c.&#xD;
             Patients who have received prior taxane therapy may be enrolled.&#xD;
&#xD;
          8. Patients with thymic carcinoma must have received at least one prior systemic&#xD;
             chemotherapy regiment for metastatic, recurrent, locally advanced or otherwise&#xD;
             unresectable disease.&#xD;
&#xD;
          9. ≥ 18 years of age&#xD;
&#xD;
         10. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST&#xD;
             1.1, see Section 9)&#xD;
&#xD;
         11. Karnofsky performance Status ≥ 70% (Section 15)&#xD;
&#xD;
         12. Male or female patients of child-producing potential must agree to use contraception&#xD;
             or avoidance of pregnancy measures during the study and for 30 days after the last&#xD;
             BBI608 dose&#xD;
&#xD;
         13. Females of childbearing potential must have a negative serum pregnancy test&#xD;
&#xD;
         14. Aspartate transaminase (AST) and alanine transaminase (ALT) £1.5 × upper limit of&#xD;
             normal (ULN), or ≤ 2.5 × ULN with metastatic liver disease&#xD;
&#xD;
         15. Hemoglobin (Hgb) ≥ 10 g/dl&#xD;
&#xD;
         16. Total bilirubin £ 1.5 × ULN&#xD;
&#xD;
         17. Creatinine £ 1.5 ´ ULN or creatinine clearance &gt; 60 mL/min/1.73 m2 for patients with&#xD;
             creatinine levels above institutional normal&#xD;
&#xD;
         18. Absolute neutrophil count ³ 1.5 x 109/L&#xD;
&#xD;
         19. Platelets ≥ 100 x 109/L&#xD;
&#xD;
         20. Life expectancy ≥ 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents&#xD;
             within 7 days of first dose provided all treatment-related adverse events have&#xD;
             resolved or have been deemed irreversible, with the exception for a single dose&#xD;
             radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up&#xD;
             to 7 days before beginning the administration of BBI608.&#xD;
&#xD;
          2. Surgery within 4 weeks prior to first dose&#xD;
&#xD;
          3. Any known symptomatic brain metastases requiring steroids. Patients with treated brain&#xD;
             metastases must be stable for 4 weeks after completion of that treatment, with image&#xD;
             documentation required. Patients must have no clinical symptoms from brain metastases&#xD;
             and must be either off steroids or on a stable dose of steroids for at least 2 weeks&#xD;
             prior to protocol enrollment. Patients with known leptomeningeal metastases are&#xD;
             excluded, even if treated&#xD;
&#xD;
          4. Pregnant or breastfeeding&#xD;
&#xD;
          5. Significant gastrointestinal disorder(s), in the opinion of the Principal&#xD;
             Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small&#xD;
             intestine resection)&#xD;
&#xD;
          6. Unable or unwilling to swallow BBI608 capsules daily&#xD;
&#xD;
          7. Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, clinically significant non-healing or healing wounds, symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant&#xD;
             pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled&#xD;
             infection or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          8. Known severe hypersensitivity to paclitaxel&#xD;
&#xD;
          9. Abnormal ECGs (ie, QT prolongation - QTc &gt; 480 msec, signs of cardiac enlargement or&#xD;
             hypertrophy, bundle branch block, signs of ischemia or necrosis and Wolff Parkinson&#xD;
             White patterns)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Lebedinsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sumitomo Dainippon Pharma Oncology, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC - University of Southern California Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prisma Health (formerly Institute for Translational Oncology Research)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center Cancer Institute</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, P.C.</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Oncology- Northwest Cancer Specialists</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center-Glenn Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 25, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BBI608, thymic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

